Changgui Li

8.5k citations

102 papers · 3.2k · 2 hit papers · h-index 24

Impact in

Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
Health top 1%
- Vaccine Coverage and Hesitancy

Papers in

Epidemiology 61
- Influenza Virus Research Studies 40
- Respiratory viral infections research 29
- Cervical Cancer and HPV Research 9
Infectious Diseases 26
- SARS-CoV-2 and COVID-19 Research 16
- Viral gastroenteritis research and epidemiology 11

Co-authors: Xuguang Li (33 shared papers)Junzhi Wang (32 shared papers)Fengcai Zhu (8 shared papers)Hongxing Pan (4 shared papers)Weidong Yin (4 shared papers)Qiang Gao (6 shared papers)Kai Chu (8 shared papers)Yuansheng Hu (4 shared papers)
Journals: Vaccine (17 papers)Human Vaccines & Immunotherapeutics (13 papers)The Journal of Infectious Diseases (6 papers)Scientific Reports (5 papers)Vaccines (4 papers)
Partner nations: China Canada Saudi Arabia

In The Last Decade

Changgui Li

99 papers receiving 3.1k citations

Changgui Li's Hit Papers

align trajectories log scale

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial 2021 · 215 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Lancet Infectious Diseases
2020 The Lancet Infectious Diseases

Peers

Countries citing papers authored by Changgui Li

Since Specialization

Citations

This map shows the geographic impact of Changgui Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changgui Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changgui Li more than expected).

Fields of papers citing papers by Changgui Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changgui Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changgui Li. The network helps show where Changgui Li may publish in the future.

Co-authors

The 25 scholars most cited alongside Changgui Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Changgui Li Line = papers co-authored together Changgui Li links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial The Lancet Infectious Diseases ·Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, Weixiao Han, Zhen Chen, Rong Tang, Weidong Yin, Xin Chen, Yuansheng Hu, Xiaoyong Liu, Congbing Jiang, Jingxin Li, Minnan Yang, Yan Song, Xiangxi Wang, Qiang Gao, Fengcai Zhu Hit paper breakdown →	2020	956
2	A Novel Influenza A (H1N1) Vaccine in Various Age Groups New England Journal of Medicine ·Fengcai Zhu, Hua Wang, (unknown), Jian Guo Yang, Xiao Jun Lin, Xiaofeng Liang, Xuefeng Zhang, Hongxing Pan, Fanyue Meng, Yue Hu, Wendong Liu, Changgui Li, Wei Li, Xiang Zhang, Jin Mei Hu, Wei Peng, Bao Ping Yang, Pei Xi, Huaqing Wang, Jingshan Zheng	2009	290
3	Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial The Lancet ·Jiangtao Lin, Jiansan Zhang, Xiao‐Ping Dong, (unknown), Jiangting Chen, Nan Su, Qiang Gao, Zhenshan Zhang, Yuxuan Liu, Zhihong Wang, Meng Yang, Ruihua Sun, Changgui Li, Su Ching Lin, Mei Ji, Yan Liu, Xu Wang, John Wood, Zijian Feng, Yu Wang, Weidong Yin	2006	218
4	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial The Lancet Infectious Diseases ·Bihua Han, Yufei Song, Changgui Li, Wanqi Yang, Qingxia Ma, Zhiwei Jiang, Minjie Li, Xiaojuan Lian, Wenbin Jiao, Lei Wang, Qun Shu, Zhiwei Wu, Yuliang Zhao, Qi Li, Qiang Gao Hit paper breakdown →	2021	215
5	Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates Emerging Microbes & Infections ·Qian He, Qunying Mao, Chaoqiang An, Jialu Zhang, Fan Gao, Lianlian Bian, Changgui Li, Zhenglun Liang, Miao Xu, Junzhi Wang	2021	103
6	Universal anti-neuraminidase antibody inhibiting all influenza A subtypes Antiviral Research ·Tracey M. Doyle, Anwar M. Hashem, Changgui Li, Gary Van Domselaar, Louise Larocque, Junzhi Wang, Daryl G.S. Smith, Terry D. Cyr, Aaron Farnsworth, Runtao He, Aeron C. Hurt, Earl G. Brown, Xuguang Li	2013	94
7	Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins Vaccine ·Stella Chun, Changgui Li, Gary Van Domselaar, Junzhi Wang, Aaron Farnsworth, Xiaoyu Cui, Harold Rode, Terry D. Cyr, Runtao He, Xuguang Li	2008	67
8	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine Emerging Microbes & Infections ·(unknown), Qian He, Chaoqiang An, Qunying Mao, Fan Gao, Lianlian Bian, Wu Xing, Qian Wang, Pei Liu, Lifang Song, Yaqian Huo, Siyuan Liu, Xujia Yan, Jinghuan Yang, Bopei Cui, Changgui Li, Junzhi Wang, Zhenglun Liang, Miao Xu	2021	65
9	Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences Vaccine ·Caroline Gravel, Changgui Li, Junzhi Wang, Anwar M. Hashem, Bozena Jaentschke, Kangwei Xu, Barry Lorbetskie, Geneviève Gingras, Yves Aubin, Garry Van Domselaar, Michel Girard, Runtao He, Xuguang Li	2010	59
10	Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial The Journal of Infectious Diseases ·Guoyang Liao, Rongcheng Li, Changgui Li, Mingbo Sun, Yanping Li, Jiayou Chu, Shude Jiang, Qihan Li	2011	58
11	Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model Scientific Reports ·Mei Zheng, Di Qu, Haiming Wang, Zhiping Sun, Xueying Liu, Jianjun Chen, Changgui Li, Xuguang Li, Ze Chen	2016	56
12	Real-time RT-PCR for H5N1 avian influenza A virus detection Journal of Medical Microbiology ·Weijun Chen, Bo He, Changgui Li, Xiaowei Zhang, Weili Wu, Xuyang Yin, Baoxing Fan, Xingliang Fan, Jian Wang	2007	53
13	Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus Biochemical and Biophysical Research Communications ·Anwar M. Hashem, Gary Van Domselaar, Changgui Li, Junzhi Wang, Yi‐Min She, Terry D. Cyr, Jianhua Sui, Runtao He, Wayne A. Marasco, Xuguang Li	2010	46
14	A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains Biochemical and Biophysical Research Communications ·Tracey M. Doyle, Changgui Li, Doris J. Bucher, Anwar M. Hashem, Gary Van Domselaar, Junzhi Wang, Aaron Farnsworth, Yi‐Min She, Terry D. Cyr, Runtao He, Earl G. Brown, Aeron C. Hurt, Xuguang Li	2013	43
15	A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide Nature Protocols ·Changgui Li, Bozena Jaentschke, Yingli Song, Junzhi Wang, Terry D. Cyr, Gary Van Domselaar, Runtao He, Xuguang Li	2009	36
16	Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC–MSE Vaccine ·(unknown), Changgui Li, Junzhi Wang, Michel Girard, Barry Lorbetskie, Caroline Gravel, Aaron Farnsworth, Xuguang Li, Daryl G.S. Smith, Terry D. Cyr	2012	36
17	Protection against Multiple Subtypes of Influenza Viruses by Virus-Like Particle Vaccines Based on a Hemagglutinin Conserved Epitope BioMed Research International ·Shaoheng Chen, Dan Zheng, Changgui Li, Wenjie Zhang, Wenting Xu, Xueying Liu, Fang Fang, Ze Chen	2015	34
18	Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China Biologicals ·Changgui Li, Ming Shao, Xiaoyu Cui, Yingli Song, Juan Li, Liyong Yuan, (unknown), Zhenglun Liang, Terry D. Cyr, Fengxiang Li, Xuguang Li, Junzhi Wang	2010	34
19	CD40 Ligand Preferentially Modulates Immune Response and Enhances Protection against Influenza Virus The Journal of Immunology ·Anwar M. Hashem, Caroline Gravel, Ze Chen, Yinglei Yi, Monika Tocchi, Bozena Jaentschke, Xingliang Fan, Changgui Li, Michael Rosu‐Myles, Alexander Pereboev, Runtao He, Junzhi Wang, Xuguang Li	2014	30
20	Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain Vaccine ·Aaron Farnsworth, Terry D. Cyr, Changgui Li, Junzhi Wang, Xuguang Li	2011	29

About Changgui Li

Changgui Li is a scholar working on Epidemiology, Infectious Diseases, Cardiology and Cardiovascular Medicine, Immunology and Molecular Biology, having authored 102 papers that have together received 3.2k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (40 papers), Respiratory viral infections research (29 papers), Viral Infections and Immunology Research (18 papers), SARS-CoV-2 and COVID-19 Research (16 papers), Viral gastroenteritis research and epidemiology (11 papers), Cervical Cancer and HPV Research (9 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Immunotherapy and Immune Responses (8 papers). The work is most often cited by research in Infectious Diseases (1.5k citations), Health (393 citations), Epidemiology (1.4k citations), Modeling and Simulation (127 citations) and Immunology (516 citations). Changgui Li has collaborated with scholars based in China, Canada and Saudi Arabia. Frequent co-authors include Xuguang Li, Junzhi Wang, Fengcai Zhu, Hongxing Pan, Weidong Yin, Qiang Gao, Kai Chu, Yuansheng Hu, Weixiao Han and Rong Tang. Their work appears in journals such as Vaccine, Human Vaccines & Immunotherapeutics, The Journal of Infectious Diseases, Scientific Reports and Vaccines.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Changgui Li

Impact in

Papers in i

In The Last Decade

Changgui Li

Changgui Li's Hit Papers

Peers

Countries citing papers authored by Changgui Li

Fields of papers citing papers by Changgui Li

All Works

About Changgui Li

Explore authors with similar magnitude of impact

Papers in